Archived research. Equity forecasting is part of the Runchey Research archive (methodology era 1) and is no longer actively updated. Everything remains published at its original URL. Browse the archive
Will WVE-007 Phase IIa 6-month data show total body weight loss of 5% or greater in the 240mg cohort?
Current Prediction
Why This Question Matters
WVE-007 6-month weight loss data is the single most important near-term catalyst. The Myth Meter flagged elevated expectations, while the Moat Mapper identified the obesity program as a genuine differentiator. Above 5% total body weight loss at 6 months would validate the mechanism; below would deflate the obesity narrative and potentially reprice the stock materially lower.
Prediction Distribution
Individual Predictions(9 runs)
Phase I data suggests 5% is borderline - requires meaningful amplification from single to multi-dose. Multi-dose should amplify Phase I effect provides partial support, but phase i 3-month only showed ~2-3% weight loss creates counterweight. Probability: 0.33.
Phase I data suggests 5% is borderline - requires meaningful amplification from single to multi-dose. Multi-dose should amplify Phase I effect provides partial support, but phase i 3-month only showed ~2-3% weight loss creates counterweight. Probability: 0.45.
Phase I data suggests 5% is borderline - requires meaningful amplification from single to multi-dose. Multi-dose should amplify Phase I effect provides partial support, but phase i 3-month only showed ~2-3% weight loss creates counterweight. Probability: 0.25.
Base rate evidence: phase i 3-month only showed ~2-3% weight loss. Partial offset from multi-dose should amplify phase i effect. Phase I data suggests 5% is borderline - requires meaningful amplification from single to multi-dose. Probability: 0.34.
Base rate evidence: phase i 3-month only showed ~2-3% weight loss. Partial offset from multi-dose should amplify phase i effect. Phase I data suggests 5% is borderline - requires meaningful amplification from single to multi-dose. Probability: 0.36.
Base rate evidence: phase i 3-month only showed ~2-3% weight loss. Partial offset from multi-dose should amplify phase i effect. Phase I data suggests 5% is borderline - requires meaningful amplification from single to multi-dose. Probability: 0.31.
Phase I data suggests 5% is borderline - requires meaningful amplification from single to multi-dose. Balance of evidence suggests 0.39 probability. Primary support: multi-dose should amplify phase i effect. Main counterargument: phase i 3-month only showed ~2-3% weight loss.
Phase I data suggests 5% is borderline - requires meaningful amplification from single to multi-dose. Balance of evidence suggests 0.38 probability. Primary support: multi-dose should amplify phase i effect. Main counterargument: phase i 3-month only showed ~2-3% weight loss.
Phase I data suggests 5% is borderline - requires meaningful amplification from single to multi-dose. Balance of evidence suggests 0.52 probability. Primary support: multi-dose should amplify phase i effect. Main counterargument: phase i 3-month only showed ~2-3% weight loss.
Resolution Criteria
Resolves YES if Wave reports mean total body weight loss of 5% or greater from baseline in the 240mg cohort at 6 months in any public disclosure. Resolves NO if weight loss is below 5% or if data is not reported by June 30, 2026.
Resolution Source
Wave Life Sciences press release, conference presentation, or SEC filing
Source Trigger
WVE-007 6-month data is the single most important near-term catalyst; Phase I 240mg single-dose showed fat loss but limited total body weight loss at 3 months
Full multi-lens equity analysis